期刊文献+

Engineered stem cells by emerging biomedical stratagems

原文传递
导出
摘要 Stem cell therapy holds immense potential as a viable treatment for a widespread range of intractable disorders.As the safety of stem cell transplantation having been demonstrated in numerous clinical trials,various kinds of stem cells are currently utilized in medical applications.Despite the achievements,the therapeutic benefits of stem cells for diseases are limited,and the data of clinical researches are unstable.To optimize tthe effectiveness of stem cells,engineering approaches have been developed to enhance their inherent abilities and impart them with new functionalities,paving the way for the next generation of stem cell therapies.This review offers a detailed analysis of engineered stem cells,including their clinical applications and potential for future development.We begin by briefly introducing the recent advances in the production of stem cells(induced pluripotent stem cells(ipsCs),embryonic stem cells(ESCs),mesenchymal stem cells(MSCs)and hematopoietic stem cells(HSCs).Furthermore,we present the latest developments of engineered strategies in stem cells,including engineered methods in molecular biology and biomaterial fields,and their application in biomedical research.Finally,we summarize the current obstacles and suggest future prospects for engineered stem cells in clinical translations and biomedical applications.
出处 《Science Bulletin》 SCIE EI CAS CSCD 2024年第2期248-279,共32页 科学通报(英文版)
基金 supported by the National Key Research and Development Program of China(2022YFA1105300) the National Natural Science Foundation of China(T2225003,82100664,and 82270646) the Jiangsu Provincial Science and Technology Special Fund for Outstanding Young Scholars(BK20230051) the Nanjing Health Science and Technology Development Project for Distinguished Young Scholars(JQX22003) fundings for Clinical Trials from the Affiliated Drum Tower Hospital,Medical School of Nanjing University(2021-LCYJ-PY-46,2022-LCYJ-PY-35) the Nanjing Medical Science and Technique Development Foundation(ZKX21019) Guangdong Basic and Applied Basic Research Foundation(2021B1515120054) the Shenzhen Science and Technology Program(JCYJ20210324133214038 and JCYJ20190813152616459).
  • 相关文献

参考文献6

二级参考文献36

  • 1Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 2006; 126:663-676.
  • 2Das S, Becker BN, Hoffmann FM, Mertz JE. Complete reversal of epithelial to mesenchymal transition requires inhibition of both ZEB expression and the Rho pathway. BMC Cell Biol 2009; 10:94.
  • 3Polo JM, Hochedlinger K. When fibroblasts MET iPSCs. Cell Stem Cell 2010; 7:5-6.
  • 4Li R, Liang J, Ni S, et al. A mesenchymal-to-epithelial transi, tion initiates and is required for the nuclear reprogramming of mouse fibroblasts. Cell Stem Cell 2010; 7:51-63.
  • 5Kim JB, Sebastiano V, Wu G, et al. Oct4-induced pluripo tency in adult neural stem cells. Cell 2009; 136:411-419.
  • 6Zhao Y, Yin X, Qin H, et al. Two supporting factors greatly improve the efficiency of human iPSC generation. Cell Stem Cell 2008; 3:475-479.
  • 7Takahashi K, Tanabe K, Ohnuki M, et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 2007; 131:861-872.
  • 8Okita K, Ichisaka T, Yamanaka S. Generation of germlinecompetent induced pluripotent stem cells. Nature 2007; 448:313-317.
  • 9Wemig M, Meissner A, Foreman R, et al. In vitro reprogramming of fibroblasts into a pluripotent ES-cell-like state. Na- ture 2007; 448:318-324.
  • 10Zhou H, Wu S, Joo JY, et al. Generation of induced pluripotent stem cells using recombinant proteins. Cell Stem Cell 2009; 4:381-384.

共引文献67

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部